Good Outcomes Obtained with New Posterior Chamber Phakic Intraocular Lens

Compared to other phakic intraocular lenses (IOLs) for correcting high myopia, a new posterior chamber phakic IOL (IPCL) shows good outcomes at 3 years and may be an effective alternative to current IOLs, according to a prospective, observational case series involving 30 eyes.

Participants underwent implantation of the IPCL for high myopia (> -8.00 diopters [D]). Measurements were taken 3 years later. Among the results:

• The mean spherical equivalent decreased from -16.5 to -0.89 D.
• The mean uncorrected and corrected distance visual acuities (UDVA and CDVA) were 0.38 and 0.24 logMAR, respectively.
• None of the eyes lost any lines and half of eyes gained ≥1 line of CDVA.
• Adverse events included anterior subcapsular cataract (1 case that did not require surgery) and mild transient increase in intraocular pressure (2 cases, both of which required brief topical medication).
• 10% of endothelial cells were lost.
• The IPCL vault decreased over the study from a mean of 626.66 μm at 1 month to 540.22 μm at 3 years.
• No vision-threatening complications occurred.

Vasavada V, Srivastava S, Vasavada SA, Sudhalkar A, Vasavada AR, Vasavada VA. Safety and Efficacy of a New Phakic Posterior Chamber IOL for Correction of Myopia: 3 Years of Follow-up. J Refract Surg. 2018;34(12):817-823. doi: 10.3928/1081597X-20181105-01.